July SMC decisions
The Scottish Medicines Consortium has announced this month’s decisions on medicines for use in NHS Scotland. Alemtuzumab has been accepted for use for relapsing remitting multiple sclerosis in adult patients with active disease. Botulinum toxin A has been accepted for use for bladder dysfunction in patients who cannot be managed with anticholinergics or available oral therapies. Certolizumab pegol has been accepted for restricted use in combination with methotrexate for the treatment of psoriatic arthritis in adults when response to two previous disease-modifying antirheumatic drug therapies has been inadequate. Certolizumab pegol can be given as monotherapy when methotrexate is inappropriate or the the patient is intolerant to methotrexate. Dapagliflozin has been accepted for restricted use for adults with type II diabetes mellitus to improve glycaemic control. It is restricted to use in triple therapy in combination with metformin and sulphonylurea, as an alternative to dipeptidyl peptidase-4 (DPP-4) inhibitors. Rituximab has been accepted for restricted use for non-Hodgkin’s lymphoma within its licensed indication except for patients receiving maintenance treatment, where use is restricted to patients who have responded to induction therapy with rituximab plus chemotherapy. Pomalidomide, in combination with dexamethasone, has not been accepted for relapsed and refractory mutliple myeloma patients because it was not considered value for money.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20065758